Spark Therapeutics
NEWS
This week, Roche said it extended its tender-offer period for outstanding shares of Spark to Oct. 1 from Sept. 3.
Roche and Spark initially agreed to the acquisition in February of this year. The deal has had mutiple delays due to regulatory scrutiny.
As fireworks illuminate the night skies across the United States this weekend in celebration of Independence Day, BioSpace takes a look at some of the highlights of the pharma industry from the first half of 2019 and earlier that provides millions of patients with the independence of health.
According to the poll results, 78% of respondents agree that the high costs of a gene therapy treatment are worth it, due to the fact that these options are seen as potential cures for disease.
Government agencies in the United States and U.K. are scrutinizing Roche’s planned acquisition of the gene therapy company.
The companies said they planned to give the government additional time to review the deal. This is the third delay.
This is the second extension that has been filed, this time delaying it until June 3. The companies indicate it is because U.S. authorities are taking longer than expected to review the deal.
April 17, 2019 is the 29th World Hemophilia Day, a designated day to create awareness of the disease. Hemophilia is one of a number of bleeding disorders. The blood of people with hemophilia does not clot normally as the result of insufficient clotting factor. As a result, they can bleed for a longer time.
Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics, said his company is the only biotech company that has successfully commercialized a gene therapy for a genetic disease in the United States.
JOBS
IN THE PRESS